RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/8/2019 |
| Start Date: | August 30, 2016 |
| End Date: | June 1, 2019 |
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical
activity of RRx-001 administered in combination with irinotecan.
RRx-001 is associated with resensitization to irinotecan in tumors that are previously
refractory. This effect has been attributed to the ability of RRx-001 to restore the
expression of aberrantly silenced genes, thus re-establishing pathway functions. However,
resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular
modulation, leading to improved penetration of standard chemotherapy.
activity of RRx-001 administered in combination with irinotecan.
RRx-001 is associated with resensitization to irinotecan in tumors that are previously
refractory. This effect has been attributed to the ability of RRx-001 to restore the
expression of aberrantly silenced genes, thus re-establishing pathway functions. However,
resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular
modulation, leading to improved penetration of standard chemotherapy.
This dose escalation study consists of 5 sequential dose cohorts each administered RRx-001
with irinotecan. After the first 3 subjects of each cohort complete Cycle 1, the safety will
be assessed before moving to the next dose level. Subjects in the current cohort will
continue treatment immediately following the completion of Cycle 1, for as long as therapy is
tolerated and the RECIST v.1.1 definition of progression is not met.
with irinotecan. After the first 3 subjects of each cohort complete Cycle 1, the safety will
be assessed before moving to the next dose level. Subjects in the current cohort will
continue treatment immediately following the completion of Cycle 1, for as long as therapy is
tolerated and the RECIST v.1.1 definition of progression is not met.
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid
tumor(s) with all standard treatment options having been exhausted or declined.
- Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening.
- Measurable disease per RECIST v1.1 by radiographic techniques
- Acceptable liver function, serum creatinine and hematological status
- Female subjects of childbearing potential, and male subjects with partners of
childbearing potential, must agree to use medically acceptable methods of
contraception beginning on Study Day 1 and continuing until at least four weeks after
administration of the subject's final dose of RRx-001.
- Subjects with brain metastases are eligible
Exclusion Criteria:
- Concurrent anticancer therapy; however, radiotherapy is allowed
- Any history of hypersensitivity to irinotecan
- Cholangitis that required treatment or intervention within 4 weeks of study enrollment
- Bilirubin > 2.0 mg/dL
- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study
- If female, subject is pregnant and/or breastfeeding.
- UGT1A1*28 homozygote or heterozygote
- BMI >35
We found this trial at
2
sites
University of California-Davis As we begin our second century, UC Davis is poised to become...
Click here to add this to my saved trials
Click here to add this to my saved trials